Elevated liver enzymes is not an impediment to allopurinol dose escalation: an observational cohort study
Rattachement africain : sg. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: Routine liver enzyme monitoring is advocated while on allopurinol but supporting guidance is lacking. We assessed the incidence and factors associated with elevated liver enzymes in gout patients commenced on allopurinol. METHODS: 150 patients with gout and normal baseline serum aminotransferases initiated on allopurinol were followed prospectively over three visits. Raised transaminases were defined as mild, moderate or severe if AST or ALT was raised <2, 2-3 or >3 times above upper normal limits, respectively. Predictors of AST/ALT elevation were assessed using Generalized Estimating Equations. RESULTS: Mean age was 56.6 years, 95.3% were men. Median follow-up was 33.5(IQR 22.8-53.1) weeks. 32(21.5%) drank alcohol, 43(28.9%) were obese and 11(7.3%) had metabolic dysfunction-associated steatotic liver disease. 30(20.0%) developed raised AST/ALT during follow-up, majority (86.7%) was mild while none were severe. Allopurinol was maintained or increased in 18 out of 19 patients with raised serum aminotransferases at Visit-2. Their elevated AST/ALT remained stable (27.8%), improved (11.1%) or resolved (33.3%) at subsequent visit. None had worsening AST/ALT. Multivariate analysis revealed that alcohol consumption (adjusted OR 3.52, 95%CI 1.41-8.79) and statin non-user (adjusted OR 3.41, 95%CI 1.04-11.17) were independent predictors of raised transaminases. Higher allopurinol dose was not associated with development of liver enzyme elevation (p=0.193). CONCLUSION: Mild asymptomatic AST/ALT elevation is common among gout patients and is not influenced by allopurinol dose escalation. Alcohol consumption was an independent risk factor for elevated liver enzymes while statin use appeared protective. Allopurinol can be safely escalated despite mild-moderate serum aminotransferase elevation.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Elevated liver enzymes is not an impediment to allopurinol dose escalation: an observational cohort study
- Date Crossref
- 07/09/2026
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
National University of Singapore Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
National University Hospital Division of Rheumatology and Allergy pays non établi dans la noticeÉtablissement de santé
-
Alexandra Hospital Department of Medicine pays non établi dans la noticeÉtablissement de santé
Department of Medicine — National University of Singapore, Division of Rheumatology and Allergy — National University Hospital et Department of Medicine — Alexandra Hospital.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.